SpeeDx steps into limelight as sales take off

SpeeDx steps into limelight as sales take off


It is involved in one of the hottest areas of biotechnology research - antibiotic resistance - and after $20 million and years of work, SpeeDX, a developer and maker of diagnostic kits, is ramping up its product roll-out as it eyes a big lift in revenues over the next few years. In the process a decision on either a sharemarket listing or a trade sale is likely over the next 18 months, especially once it wins access to the US market and revs up its sales there.



from Biotech News